deltatrials

Malignant glioma Trials in Durham, United States

Conditions / Malignant glioma / Durham, United States

Clinical trials for Malignant glioma investigate a range of treatment strategies and patient populations.

36 total trials for this combination

Showing top 10 of 36 trials

Trials

NCT ID Title Status Phase
NCT03155620 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) ACTIVE_NOT_RECRUITING
NCT03213678 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) COMPLETED
NCT03749187 BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas ACTIVE_NOT_RECRUITING PHASE1
NCT03581292 Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations ACTIVE_NOT_RECRUITING PHASE2
NCT03233204 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) COMPLETED PHASE2
NCT03220035 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) COMPLETED PHASE2
NCT02465268 Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme COMPLETED PHASE2
NCT00458601 Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme COMPLETED PHASE2
NCT03678883 9-ING-41 in Patients with Advanced Cancers ACTIVE_NOT_RECRUITING PHASE2
NCT04323046 Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults RECRUITING PHASE1

Related Pages